Where can I find news about RHHBY?

The latest press releases, SEC filings, and earnings call transcripts for Roche Holding AG (RHHBY) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.

Where are RHHBY's SEC filings?

Roche Holding AG (RHHBY)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

When was RHHBY's last earnings call?

The most recent earnings call transcript for Roche Holding AG (RHHBY) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

RHHBY

Roche Holding AG

OTC·Drug Manufacturers, General · Healthcare

$51.70$0.56+1.10%

After hours·$51.70+0.00%

Market cap$332.99B·Market closed·Jul 22 8:00 PM UTC

Press Releases

Roche Backs Full-Year View as First-Half Sales Rise
The drugmaker's sales grew 6% on a constant exchange rate basis and exceeded analysts' expectations, according to a company compiled consensus.
wsj.comJul 23, 2026 · 1:40 AM
Roche confirms full year targets as first-half sales fall
Swiss drugmaker Roche confirmed its full-year targets on Thursday as first-half ‌sales fell in Swiss franc terms, dragged down by a strong domestic currency.
reuters.comJul 23, 2026 · 1:17 AM
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer Frankens
Konzernverkäufe stiegen in den ersten sechs Monaten um6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -2% und auf USD-Basis28%) aufgrund hoher Nachfrage nach innovativen Medikamenten und Diagnostika. Verkäufe der Division Pharma erhöhten sich um6% (CER; in CHF ausgewiesen -1% und auf USD-Basis8%) aufgrund des kontinuierlich hohen Umsatzwachstums unserer Medikamente in allen Therapiebereichen; die wichtigsten Wachstumstreiber waren Xolair (allergisches Asthma, chronische Nesselsucht, Nahrungsmittelallergien), Hemlibra (Hämophilie A), Ocrevus (Multiple Sklerose), Phesgo (Brustkrebs) und Vabysmo (schwere Augenerkrankungen).
globenewswire.comJul 23, 2026 · 1:00 AM
The Hanover Announces CEO Succession Plan: John C. Roche to Retire as President and CEO at the End of 2026; Chief Operating Officer Richard W.
WORCESTER, Mass., July 15, 2026 /PRNewswire/ -- The Hanover Insurance Group, Inc., (NYSE: THG), a leading property and casualty insurance company, announced today that John "Jack" C.
prnewswire.comJul 15, 2026 · 4:35 PM
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
zacks.comJul 15, 2026 · 1:10 PM
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
marketbeat.comJul 8, 2026 · 12:36 PM
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
zacks.comJul 3, 2026 · 2:46 PM
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Experimental drug, divarasib, showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening.
wsj.comJul 2, 2026 · 1:50 AM

SEC Filings

No recent filings indexed.

Transcripts

PRO

Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.

Click below to see what's inside, then upgrade to read every transcript for RHHBY and 80,000+ other tickers.

Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.

Frequently Asked Questions About RHHBY

Where can I find news about RHHBY?: The latest press releases, SEC filings, and earnings call transcripts for Roche Holding AG (RHHBY) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.
Where are RHHBY's SEC filings?: Roche Holding AG (RHHBY)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
When was RHHBY's last earnings call?: The most recent earnings call transcript for Roche Holding AG (RHHBY) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

Roche Holding AG

Frequently Asked Questions About RHHBY

Roche Holding AG

Roche Backs Full-Year View as First-Half Sales Rise

Roche confirms full year targets as first-half sales fall

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer Frankens

The Hanover Announces CEO Succession Plan: John C. Roche to Retire as President and CEO at the End of 2026; Chief Operating Officer Richard W.

RHHBY's Gazyva Gets FDA Priority Review for Label Expansion

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug

Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial

Frequently Asked Questions About RHHBY

Roche Backs Full-Year View as First-Half Sales Rise

Roche confirms full year targets as first-half sales fall

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer Frankens

The Hanover Announces CEO Succession Plan: John C. Roche to Retire as President and CEO at the End of 2026; Chief Operating Officer Richard W.

RHHBY's Gazyva Gets FDA Priority Review for Label Expansion

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug

Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial